Evidence map›Paper›PMID 42421521›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2026

AI-Optimized 3D-Printed Dual-Layer Implant: Resolving Chemo-Immunotherapy Sequential Administration Dilemma for Colorectal Cancer Peritoneal Metastasis.

Weiyi Tang, Bing Liu, Ye Liu, Shuai Wang, Tiancong Zhao, Jiaqi Wang, Chen Jiang, Tao Sun

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weiyi TangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, State Key Laboratory of Brain Function and Disorders, Ministry of Education, Fudan University, Shanghai, China.
Bing LiuDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, State Key Laboratory of Brain Function and Disorders, Ministry of Education, Fudan University, Shanghai, China.
Ye LiuDepartment of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China.
Shuai WangDepartment of Chemistry, Engineering Center of Catalysis and Synthesis for Chiral Molecules, Shanghai Engineering Research Center of Industrial Asymmetric Catalysis of Chiral Drugs, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-0718-1820
Tiancong ZhaoCollege of Smart Materials and Future Energy, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-1995-2274
Jiaqi WangDepartment of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong SAR, China.
Chen JiangDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, State Key Laboratory of Brain Function and Disorders, Ministry of Education, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0001-5223-2725
Tao SunDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, State Key Laboratory of Brain Function and Disorders, Ministry of Education, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-1049-1216

Funding

National Key R&D Program of China 2024YFA1210203National Natural Science Foundation of China 2023YFC3404103National Natural Science Foundation of China 82361148716National Natural Science Foundation of China 82473853Shanghai Municipal Science and Technology Commission through the International Science and Technology Cooperation Program of the Science and Technology Innovation Action Plan 24430710700Shanghai Municipal Science and Technology Major Project 2018SHZDZX01
6 · The paper itself

Abstract

The synergistic integration of chemotherapy and immunotherapy represents the most promising strategy for enhancing therapeutic efficacy in cancer treatment. Chemotherapy initiates the therapeutic cascade by inducing immunogenic cell death (ICD), thereby releasing tumor antigens and prime immune sensitization. Subsequently, immunotherapy blocks immune evasion pathways, resulting in a coordinated relay-like antitumor response. This temporally coordinated sequence maximizes synergistic therapeutic efficacy. However, current clinical practice cannot support the sequential and sustained administration of chemotherapy and immunotherapy. This study innovatively integrates artificial intelligence (AI) with 3D printing technology to develop a dual-layer drug-loaded implant (LEH@OG) to achieve precise spatiotemporally controlled sequential drug release. The AI model precisely predicted exposure time of the inner gel layer in advance by optimizing parameters such as outer shell thickness and concentration, thereby realizing an on-demand sequential release process. This study demonstrates that combining AI with 3D printing enables precise sequential delivery of chemotherapy-immunotherapy agents, providing a core solution for establishing personalized colorectal cancer peritoneal metastasis (CCPM) therapeutic platforms, while also offering a new paradigm for synergistic treatment of other solid tumors.

Indexed as

Antineoplastic AgentsArtificial IntelligenceColorectal NeoplasmsImmunotherapyPeritoneal NeoplasmsPrinting, Three-DimensionalAnimalsCell Line, TumorDrug ImplantsDrug LiberationHumansMiceAntineoplastic AgentsDrug Implants3D printingartificial intelligencedrug delivery systemperitoneal metastasessequential releaseTGF‐β/SMAD signaling pathway

Identifiers

PMID42421521
PMCPMC13471880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.